Novel bacteriophage having specific killing ability against Clostridium perfringens and antibacterial composition containing the same

Bacteriophage CJ_CP_20-11-1 addresses Clostridium perfringens infections by specifically targeting and eliminating the bacteria, providing a broad lytic spectrum and resistance to acid and heat, suitable for use in livestock farming compositions.

JP7579986B2Active Publication Date: 2024-11-08CJ CHEILJEDANG CORP
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023551249
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-02-23
Filing Date
2021-06-15
Publication Date
2024-11-08
Estimated Expiration
2041-06-15

AI Technical Summary

Technical Problem

Current livestock farming is challenged by Clostridium perfringens infections, which cause severe diseases like necrotizing enterocolitis, and there is a need for effective alternatives to antibiotics due to growing restrictions on antibiotic use.

Method used

Development of bacteriophage CJ_CP_20-11-1, specifically designed to kill Clostridium perfringens, and its application in compositions for preventing or treating infectious diseases, including use as a food additive, antibiotic, feed additive, drinking water additive, disinfectant, or cleaning agent.

Benefits of technology

Bacteriophage CJ_CP_20-11-1 effectively kills Clostridium perfringens, offering broad lytic spectrum, acid and heat resistance, and reduces disease incidence without inducing drug resistance, suitable for industrial use in livestock farming.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579986000003
    Figure 0007579986000003
  • Figure 0007579986000004
    Figure 0007579986000004
  • Figure 0007579986000005
    Figure 0007579986000005
Patent Text Reader

Abstract

The present invention relates to a novel bacteriophage having specific killing ability against Clostridium perfringens, and an antibacterial composition containing the same. The novel bacteriophage CJ_CP_20-11-1 has the effect of specifically killing Clostridium perfringens and has excellent acid resistance and heat resistance, and can be widely used as an antibiotic, feed additive, drinking water additive, feed, drinking water, disinfectant or cleaning agent for the prevention or treatment of infectious diseases caused by Clostridium perfringens.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel bacteriophage having specific killing activity against Clostridium perfringens, and an antibacterial composition containing the same. [Background technology]

[0002] Clostridium perfringens is a large, gram-positive, obligately anaerobic bacillus that is non-flagellated and known to form spores. Clostridium perfringens causes diarrhea in animals, particularly livestock such as chickens and pigs, and is recognized as one of the most important and fatal pathogens in the livestock industry, comparable to poultry typhoid caused by Salmonella.

[0003] Necrotic enteritis caused by Clostridium perfringens infection, which is one of the most frequent diseases in the poultry and swine industries, causes severe necrotic lesions in the lower part of the small intestine of chickens and pigs, and causes bloody diarrhea as its main symptom. Necrotic enteritis is a very problematic disease in the livestock industry, as it causes dehydration and intermittent diarrhea in infected animals depending on the severity of the disease, gradually weakening the animal's body and inducing growth retardation. Furthermore, Clostridium perfringens, which causes necrotic enteritis, is easily transmitted through animal feces, and can easily infect animals in a shared breeding space through oral infection through soil or contaminated feed, and the incidence rate is particularly high in young livestock, which is even more problematic.

[0004] In the livestock industry and other fields, various antibiotics have been used to prevent and treat diseases caused by bacterial infections in livestock. However, problems such as misuse, overuse, resistance, and the possibility of antibiotics remaining in the bodies of animals have emerged, and currently many restrictions are placed on the administration of antibiotics worldwide.

[0005] As a result, bacteriophages, which are bacteria-specific viruses that infect specific bacteria and inhibit their growth, have recently been researched as new alternatives to antibiotics because they have stronger host specificity than antibiotics. However, the reality is that there is still an absolute shortage of these phages.

[0006] Therefore, in order to prevent and treat infectious diseases caused by Clostridium perfringens, which is a major problem in the livestock industry, including pig and poultry farming, there is a continuing need to develop new bacteriophages that have a broad lytic spectrum, excellent acid resistance and heat resistance, and have high potential for industrial use. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] US6,942,858 B1 Summary of the Invention [Problem to be solved by the invention]

[0008] The object of the present invention is to provide bacteriophage CJ_CP_20-11-1, which has specific killing ability against Clostridium perfringens and has been deposited under deposit number KCCM12932P, a composition for preventing or treating infectious diseases caused by Clostridium perfringens containing the bacteriophage CJ_CP_20-11-1 as an active ingredient, an antibiotic, a feed additive, a drinking water additive, a disinfectant, or a cleaning agent, or feed containing the feed additive, or drinking water containing the drinking water additive.

[0009] Another object of the present invention is to provide a method for preventing or treating an infectious disease caused by Clostridium perfringens using the bacteriophage CJ_CP_20-11-1 or a composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the same as an active ingredient.

[0010] It is yet another object of the present invention to provide a use of the bacteriophage CJ_CP_20-11-1 or a composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the same as an active ingredient, for the manufacture of an agent for preventing or treating an infectious disease caused by Clostridium perfringens. [Means for solving the problem]

[0011] Each description and embodiment disclosed in the present invention can be applied to each other description and embodiment. That is, all combinations of various elements disclosed in the present invention belong to the scope of the present invention. In addition, the scope of the present invention is not limited by the specific description described below. In addition, a person having ordinary skill in the art can recognize or ascertain many equivalents to the specific aspects of the present invention described in the present invention using only routine experimentation. In addition, such equivalents are intended to be included in the present invention.

[0012] One embodiment provides bacteriophage CJ_CP_20-11-1, which has specific killing ability against Clostridium perfringens and has been deposited under deposit number KCCM12932P.

[0013] The term "Clostridium perfringens (CP)" used herein corresponds to a gram-positive anaerobic bacillus, which is a causative agent of infectious diseases in animals such as chickens and pigs.

[0014] As used herein, the term "bacteriophage" refers to a bacteria-specific virus that infects and inhibits the growth of a specific bacterium and contains single- or double-stranded DNA or RNA as its genetic material.

[0015] Another aspect provides a composition for preventing or treating an infectious disease caused by Clostridium perfringens, comprising the bacteriophage CJ_CP_20-11-1 as an active ingredient.

[0016] The bacteriophage CJ_CP_20-11-1 is as described above.

[0017] Since the bacteriophage CJ_CP_20-11-1 has a specific killing ability against Clostridium perfringens, when it is administered to an individual before the onset of an infectious disease caused by Clostridium perfringens, it can kill the Clostridium perfringens that enters the individual, suppress the infection caused by the Clostridium perfringens, and prevent the infectious disease caused by Clostridium perfringens. Furthermore, when the bacteriophage CJ_CP_20-11-1 is administered to an individual who has developed an infectious disease caused by Clostridium perfringens, it can kill the Clostridium perfringens present in the individual, thereby alleviating or eliminating the symptoms caused by the Clostridium perfringens, and treating the infectious disease caused by Clostridium perfringens.

[0018] As used herein, the term "prevention" refers to any action by which the administration of a bacteriophage or composition inhibits or delays the onset of disease in an individual, and the term "treatment" refers to any action by which the administration of a bacteriophage or composition improves, alleviates, or eliminates symptoms of disease in an individual.

[0019] The infectious disease caused by Clostridium perfringens is, for example, necrotizing enteritis, but is not limited thereto.

[0020] The term "necrotic enteritis" as used herein refers to an infectious disease caused by Clostridium perfringens, which is a bacterial disease that frequently occurs in livestock such as meat chickens and causes considerable damage. The symptoms of necrotic enteritis are caused by excessive proliferation of Clostridium perfringens in the small intestine, causing necrosis of the digestive mucosa and sudden diarrhea. For example, in farmed pigs, in the case of peracute necrotic enteritis, death occurs 1 to 2 days after the onset of the disease, and in the case of acute necrotic enteritis, death occurs 2 to 3 days after the discharge of bloody diarrhea. In addition, in the case of subacute necrotic enteritis, diarrhea (without bloody stool) continues for 5 to 7 days, followed by weakness and dehydration, and in the case of chronic necrotic enteritis, intermittent diarrhea may be induced, causing growth disorders.

[0021] The composition for preventing or treating an infectious disease caused by Clostridium perfringens contains the bacteriophage CJ_CP_20-11-1 at a concentration of 1×10 2 ~1×10 12 PFU / mL or 1 × 10 5 ~1×10 10 It may contain PFU / g.

[0022] The composition for preventing or treating an infectious disease caused by Clostridium perfringens may further comprise a pharma- ceutically acceptable carrier, and may be formulated together with the carrier and provided as a food, pharmaceutical, feed additive, or drinking water additive, etc.

[0023] As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent, etc., that does not irritate the body and does not inhibit the biological activity and properties of the administered compound.

[0024] The type of carrier contained in the composition is not particularly limited, and any pharma- ceutically acceptable carrier commonly used in the art can be used. Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, etc. These can be used alone or in combination of two or more, and other common additives such as antioxidants, buffers, bacteriostatic agents, etc. can be added as necessary. In addition, diluents, dispersants, binders, and lubricants can be added to the composition to form an injectable dosage form such as an aqueous solution, suspension, or emulsion, or a pill, capsule, granule, or tablet.

[0025] The composition for preventing or treating infectious diseases caused by Clostridium perfringens can be administered orally or parenterally, and can be applied or sprayed to the diseased area. In the case of parenteral administration, it can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously or topically. The appropriate application, spray and dosage of the composition vary depending on factors such as the formulation method, administration method, age, weight, sex, disease symptom level, food, administration time, administration route, excretion rate and reaction sensitivity of the target animal or patient, and an effective dosage for the intended treatment can be easily determined and prescribed by a skilled physician or veterinarian.

[0026] The composition for preventing or treating infectious diseases caused by Clostridium perfringens may be formulated as a dosage form for oral administration, for example, in the form of tablets, troches, lozenges, aqueous or oily suspensions, prepared powders or granules, emulsions, hard or soft capsules, syrups or elixirs. For formulation in dosage forms such as tablets and capsules, it may contain binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax, and in the case of capsule dosage forms, it may further contain liquid carriers such as fatty oils in addition to the above-mentioned substances.

[0027] The composition for preventing or treating infectious diseases caused by Clostridium perfringens may be formulated for parenteral administration in the form of an injection such as subcutaneous injection, intravenous injection, or intramuscular injection, a suppository injection, or a spray such as an aerosol agent that can be inhaled through the respiratory tract. To prepare the composition for injection, the composition of the present invention may be mixed with a stabilizer or buffer in water to prepare a solution or suspension, which may be formulated for unit administration in an ampoule or vial. When the composition is formulated for spray such as an aerosol agent, a propellant may be mixed with an additive so that the water-dispersed concentrate or wet powder can be dispersed.

[0028] The composition for preventing or treating an infectious disease caused by Clostridium perfringens may contain a preservative, a stabilizer, a wetting agent or an emulsifier, a cryoprotectant, or an excipient.

[0029] The preservatives, stabilizers, or excipients may be included in the composition in an effective amount sufficient to reduce deterioration of the composition.

[0030] The term "deterioration in quality" as used herein may include a decrease in the number of bacteria, a decrease in activity, or a combination thereof, of bacteriophage CJ_CP_20-11-1 contained in a composition or the like.

[0031] For example, the composition may contain an effective amount of a preservative, stabilizer, or excipient sufficient to reduce deterioration of the composition, thereby allowing bacteriophage CJ_CP_20-11-1 to survive or remain active for a longer period within the composition, unlike bacteriophages present in the natural environment, etc.

[0032] The preservative, stabilizer, or excipient may be any one commonly used in the art, as long as it can reduce the deterioration of the composition. For example, the stabilizer may be any one or more selected from the group consisting of alginate, sodium alginate, casein, sodium caseinate, cellulose, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, pectin, gelatin, gum arabic, xanthan gum, dextran, cyclodextrin, and starch.

[0033] The cryoprotectant may be included in the composition in an effective amount sufficient to reduce deterioration of the composition when the composition is in a freeze-dried state. For example, unlike bacteriophages present in a natural environment, which are reduced in activity or cannot survive in a freeze-dried composition, the composition may contain a cryoprotectant in an effective amount sufficient to reduce deterioration of the composition in a freeze-dried state, thereby maintaining bacteriophage activity or allowing the bacteriophage to survive in the freeze-dried composition.

[0034] The cryoprotectant may be any cryoprotectant commonly used in the art, as long as it is capable of reducing deterioration of the composition in a lyophilized state, and may be any one or more selected from the group consisting of glycerol, ethylene glycol, propylene glycol, dimethyl sulfoxide (DMSO), glucose, trehalose, maltodextrin, dextrin, skim milk, and starch.

[0035] Another aspect provides an antibiotic comprising the bacteriophage CJ_CP_20-11-1 as an active ingredient.

[0036] The bacteriophage CJ_CP_20-11-1 is as described above.

[0037] The term "antibiotic" as used herein means a preparation capable of killing or inhibiting the growth of bacteria, and collectively refers to antiseptics, bactericides, and antibacterial agents.

[0038] An antibiotic containing the bacteriophage CJ_CP_20-11-1 as an active ingredient has a very high specificity against Clostridium perfringens compared to conventional antibiotics, and can kill only specific pathogenic bacteria without killing beneficial bacteria. It also does not induce drug resistance, so it can show the effect of extending the product lifespan compared to conventional antibiotics.

[0039] The antibiotics can be prepared by methods commonly used in the art.

[0040] The antibiotic contains an effective amount of an additive sufficient to reduce deterioration of the antibiotic, and the additive may be a preservative, stabilizer, excipient, or cryoprotectant. The antibiotic may contain the additive, so that the bacteriophage CJ_CP_20-11-1 survives for a longer period or maintains its activity in the antibiotic, unlike the bacteriophage present in the natural state. The preservative, stabilizer, excipient, or cryoprotectant may be any preservative, stabilizer, excipient, or cryoprotectant commonly used in the art, as long as it can reduce deterioration of the antibiotic.

[0041] Another aspect provides a feed additive comprising the bacteriophage CJ_CP_20-11-1 as an active ingredient. Yet another aspect provides a feed comprising the feed additive. Yet another aspect provides a drinking water additive comprising the bacteriophage CJ_CP_20-11-1 as an active ingredient. Yet another aspect provides drinking water comprising the drinking water additive.

[0042] The bacteriophage CJ_CP_20-11-1 is as described above.

[0043] The feed additive or drinking water additive may be prepared in the form of a composition containing bacteriophage CJ_CP_20-11-1 and may be mixed with feed or drinking water, or the bacteriophage CJ_CP_20-11-1 may be directly added during the production of feed or drinking water.

[0044] The bacteriophage CJ_CP_20-11-1 contained in the feed additive or drinking water additive may be in a liquid state or a dried solid state, specifically in a dried powder form. The drying method of the bacteriophage CJ_CP_20-11-1 may be, but is not limited to, a ventilation drying, natural drying, spray drying, or freeze drying method. The bacteriophage CJ_CP_20-11-1 may be mixed in a dried powder form at 0.05 to 10 wt %, specifically 0.1 to 2 wt %, based on the weight of the feed additive or drinking water additive.

[0045] The feed additive or drinking water additive containing the bacteriophage CJ_CP_20-11-1 as an active ingredient may further contain other additives as necessary. Non-limiting examples of the additives that can be used include binders, emulsifiers, preservatives, etc., which are added to prevent deterioration of the quality of the feed or drinking water, and amino acid preparations, vitamin preparations, enzyme preparations, live bacteria preparations, flavoring agents, non-protein nitrogen compounds (NPN), silicate preparations, buffers, colorants, extractants, oligosaccharides, etc., which are added to increase the utility of the feed or drinking water, and these may be added alone or in combination of two or more.

[0046] The raw materials contained in the feed or drinking water other than the bacteriophage CJ_CP_20-11-1 may be any raw material commonly used in the art without limitation. Non-limiting examples of the feed include vegetable feed such as grains, root vegetables, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, melons, or grain by-products, and animal feed such as proteins, inorganic substances, oils and fats, minerals, oils and fats, single-cell proteins, zooplankton, or food and drink. These may be used alone or in combination of two or more.

[0047] The feed additive may be contained in an amount of 0.05 to 10 parts by weight, for example, 0.1 to 2 parts by weight, relative to 100 parts by weight of the feed, and the drinking water additive is contained in an amount of 0.0001 to 0.01 parts by weight, for example, 0.001 to 0.005 parts by weight, relative to 100 parts by weight of the drinking water.

[0048] The feed additive, feed, drinking water additive or drinking water can be produced by a production method commonly used in the art.

[0049] The feed additive, feed, drinking water additive, or drinking water contains an effective amount of an additive sufficient to reduce the deterioration of the quality thereof, and the additive may be a preservative, stabilizer, excipient, or cryoprotectant. The feed additive, feed, drinking water additive, or drinking water contains the additive, so that the bacteriophage CJ_CP_20-11-1 survives or remains active for a longer period in the feed additive, feed, drinking water additive, or drinking water, unlike the bacteriophage present in the natural state. The preservative, stabilizer, excipient, or cryoprotectant may be any preservative, stabilizer, excipient, or cryoprotectant commonly used in the art, as long as it can reduce the deterioration of the quality of the feed additive, feed, drinking water additive, or drinking water.

[0050] Another embodiment provides a disinfectant comprising the bacteriophage CJ_CP_20-11-1 as an active ingredient. Yet another embodiment provides a cleaning agent comprising the bacteriophage CJ_CP_20-11-1 as an active ingredient.

[0051] The bacteriophage CJ_CP_20-11-1 is as described above.

[0052] The formulation of the disinfectant or cleaner is not particularly limited, and may be prepared in a formulation known in the art. The disinfectant or cleaner may be prepared by a preparation method commonly used in the art.

[0053] The disinfectant is applied to eliminate Clostridium perfringens and may be applied to, but is not limited to, animal activity areas, slaughterhouses, killing areas, cooking areas or cooking equipment.

[0054] The detergent can be used for cleaning the skin surface or various parts of the body of an animal that have been exposed or may be exposed to Clostridium perfringens, but is not limited thereto.

[0055] The disinfectant or cleaning agent contains an additive in an effective amount sufficient to reduce the deterioration of the quality, and the additive may be a preservative, stabilizer, excipient, or cryoprotectant. The disinfectant or cleaning agent contains the additive, so that the bacteriophage CJ_CP_20-11-1 survives or remains active for a longer period in the disinfectant or cleaning agent, unlike the bacteriophage present in the natural state. The preservative, stabilizer, excipient, or cryoprotectant may be any preservative, stabilizer, excipient, or cryoprotectant commonly used in the art, as long as it can reduce the deterioration of the disinfectant or cleaning agent.

[0056] Another aspect provides a method for preventing or treating an infectious disease caused by Clostridium perfringens, comprising administering the bacteriophage CJ_CP_20-11-1 or a composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the bacteriophage CJ_CP_20-11-1 as an active ingredient to an animal other than a human.

[0057] The bacteriophage CJ_CP_20-11-1, the composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the bacteriophage CJ_CP_20-11-1 as an active ingredient, and the infectious disease caused by Clostridium perfringens are as described above. Specifically, the infectious disease caused by Clostridium perfringens may be, for example, necrotizing enteritis.

[0058] Specifically, the method for preventing or treating the disease comprises administering a pharma- tically effective amount of the bacteriophage CJ_CP_20-11-1 or a composition containing the same as an active ingredient to an animal other than a human that is infected or at risk of being infected with Clostridium perfringens. The bacteriophage CJ_CP_20-11-1 or a composition containing the same as an active ingredient can be administered to an animal in the form of a pharmaceutical preparation, or in the form of a feed additive or drinking water additive, by mixing the same with the animal's feed or drinking water and having the animal ingest the same.

[0059] The bacteriophage CJ_CP_20-11-1 or a composition containing it as an active ingredient can be administered by various oral or parenteral routes as long as it can reach the target tissue. Specifically, it can be administered in the usual manner, such as orally, rectally, topically, intravenously, intraperitoneally, intramuscularly, intraarterially, transdermally, intranasally, or by inhalation.

[0060] The appropriate total daily usage amount of the bacteriophage CJ_CP_20-11-1 or a composition containing it as an active ingredient can be determined by the treating physician within the scope of sound medical judgment, which is a matter of ordinary skill in the art.

[0061] The specific pharmacologic effective amount of the bacteriophage CJ_CP_20-11-1 or a composition containing it as an active ingredient for a particular animal is determined taking into consideration the type and degree of the reaction to be achieved, the age, weight, general health condition, sex, or diet of the individual, as well as the administration time, administration route, secretion rate of the composition, and treatment period of the bacteriophage CJ_CP_20-11-1 or a composition containing it as an active ingredient, and can be diversified depending on various factors including drugs and other composition components used simultaneously or at different times, and similar factors well known in the pharmaceutical field.

[0062] The animals other than humans are not particularly limited as long as they are animals that can be infected with Clostridium perfringens. For example, the animals may be birds and mammals, and specifically may include, but are not limited to, chickens, ducks, pigs, etc.

[0063] Another aspect provides use of the bacteriophage CJ_CP_20-11-1 or a composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the bacteriophage CJ_CP_20-11-1 as an active ingredient for the manufacture of an agent for preventing or treating an infectious disease caused by Clostridium perfringens.

[0064] The bacteriophage CJ_CP_20-11-1, the composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the bacteriophage CJ_CP_20-11-1 as an active ingredient, and the infectious disease caused by Clostridium perfringens are as described above. Specifically, the infectious disease caused by Clostridium perfringens may be, for example, necrotizing enteritis. Effect of the Invention

[0065] The novel bacteriophage CJ_CP_20-11-1 has the effect of specifically killing Clostridium perfringens and has excellent acid and heat resistance, and can be widely used in the prevention or treatment of infectious diseases caused by Clostridium perfringens, such as as an antibiotic, feed additive, drinking water additive, feed, drinking water, disinfectant, or cleaning agent. [Brief description of the drawings]

[0066] [Figure 1] This is an electron microscope photograph of the novel bacteriophage CJ_CP_20-11-1. [Diagram 2] 1 is a graph showing the results of confirming the pH stability of the novel bacteriophage CJ_CP_20-11-1. [Diagram 3] 1 is a graph showing the results of confirming the stability of the novel bacteriophage CJ_CP_20-11-1 at 60° C. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0067] The present invention will be described in more detail with reference to the following examples, however, these examples are merely illustrative of one or more specific examples and are not intended to limit the scope of the present invention.

[0068] Example 1. Isolation of bacteriophage capable of killing Clostridium perfringens (CP)

[0069] Example 1-1. Preparation of fecal sample pretreatment solution Fecal samples from pigs, chickens, and cattle were collected from farms in Seoul, Gyeonggi, Chungcheong, and Gyeongsang provinces, Korea. 20 g of each sample was diluted in 80 mL of PBS and centrifuged at 10,000 rpm for 15 minutes. The supernatant was filtered through a 0.2 μm filter, and 10% (w / v) sodium chloride solution was added to the filtrate and stored at 4°C for 12 hours. 10% (w / v) polyethylene glycol 8000 (Sigma-Aldrich, Cat. No. P2139) was then added and stored at 4°C for 12 hours, after which the mixture was centrifuged at 15,000 rpm for 1 hour to concentrate and the supernatant was removed. The precipitate was dissolved in 10 mL of SM buffer (5.8 g / L sodium chloride, 2 g / L MgSO4·7H2O, 0.05 M Tris-Cl (pH 7.5)), filtered through a 0.2 μm filter, and the filtrate was stored at 4 °C.

[0070] Example 1-2. Preparation of bacteriophage concentrate CP strains isolated from fecal samples collected from livestock farms in Seoul, Gyeonggi, Chungcheong, and Gyeongsang provinces, Korea, and CP strains provided by the National Veterinary Science and Quarantine Service were inoculated into 2 mL of BHI (Brain Heart Infusion) medium and cultured at 42° C. under anaerobic conditions for 18 hours, and then 1 mL of the CP strain culture and 1 mL of the fecal sample pretreatment solution obtained in Example 1-1 were inoculated into 50 mL of BHI medium and cultured at 42° C. for 18 hours. The mixed culture was centrifuged at 6,000 rpm for 20 minutes, and the supernatant was filtered through a 0.2 μm filter, and 10% (w / v) polyethylene glycol 8000 was added thereto and stored at 4° C. for 12 hours. Then, for concentration, the mixture was centrifuged at 15,000 rpm for 1 hour to remove the supernatant, and the precipitate was dissolved in 1 mL of SM buffer and filtered through a 0.2 μm filter, and the filtrate was stored at 4°C.

[0071] Examples 1-3. Screening and isolation of bacteriophages 50 μL of the bacteriophage concentrate prepared in Example 1-2 was mixed with 5 mL of 0.7% (w / v) agar (BD DIFCO, Cat. No. 44164) and 50 μL of a culture solution obtained by shaking culture of the same CP strain used in Example 1-2 to an optical density (OD) of 2 at 600 nm, and a double-layer agar plaque assay was performed using a 150 mm diameter BHI plate medium. The plaques formed on the soft agar were punched with a 200 μL tip and eluted in 0.5 mL of SM buffer. The eluted bacteriophage-containing solution was subjected to a double-layer agar plaque assay repeatedly until a single plaque of the same shape was formed, and a solution containing pure bacteriophage was isolated. The obtained bacteriophage-containing solution was filtered through a 0.2 μm filter, 10% (w / v) polyethylene glycol 8000 was added thereto, and the solution was stored at 4° C. for 12 hours. Then, the solution was centrifuged at 15,000 rpm for 1 hour to concentrate the solution, and the supernatant was removed. The precipitate was dissolved in 1 mL of SM buffer, filtered through a 0.2 μm filter, and the filtrate was stored at 4° C.

[0072] Example 2. Whole genome sequencing (WGS) analysis of isolated bacteriophages

[0073] DNA was extracted from 1 mL of the bacteriophage concentrate isolated in Example 1-3 using the CsCl gradient method and a phage DNA isolation kit (Norgen Biotek-Corp. Kit, Cat. No. 46800). Macrogen Inc. was commissioned to perform whole genome analysis, and genes were combined using de novo assembly software (SPAdes 3.13.0), and open reading frames (ORFs) were identified using GeneMark.hmm and NCBI ORF finder. The functions of each ORF were annotated using the BLASTP (E values ​​of <0.1) and PSI-BLAST (E value of <0.005) programs.

[0074] As a result, the isolated bacteriophage was confirmed to have the base sequence of SEQ ID NO: 1, which is 51,423 bp, 73 ORFs, and has a G+C content of 34.1%, which showed 97% sequence identity with the previously reported Clostridium phage CPD4 (MK017819.1), but it was confirmed that there was no bacteriophage with 100% identical fragments, and the bacteriophage was found to be a newly isolated bacteriophage. Therefore, the novel bacteriophage was named bacteriophage CJ_CP_20-11-1 and was deposited at the Korean Culture Center of Microorganisms, an international depository institution under the Budapest Treaty, on January 18, 2021, and was assigned the deposit number KCCM12932P.

[0075] Example 3. Morphological analysis of bacteriophage CJ_CP_20-11-1

[0076] In order to obtain a high-purity bacteriophage solution, a CsCl gradient method was performed. Specifically, a CsCl solution dissolved in SM buffer with a density of 1.7, 1.5, 1.45, or 1.3 was prepared, and the CsCl solution was dispensed in 2 mL portions into a 15 mL ultracentrifuge tube (Beckman Coulter, Cat. No. Z00901SCA) so as to form layers from high density to low density, and 2 mL of the bacteriophage CJ_CP_20-11-1 concentrate obtained in Example 1-3 was dispensed onto the top end. This was centrifuged at 4°C and 25,000 rpm for 2 hours, and only the white bacteriophage layer formed in the tube was collected with a syringe (Satorius, Cat. No. 17822-K). 1 μL of the collected bacteriophage solution was dropped onto a carbon-coated copper grid, which was then stained with 2% uranyl acetate for 15 seconds and the morphology was observed under an electron microscope (TEM, JEOL JEM-101, Tokyo, Japan).

[0077] As a result, as shown in Figure 1, bacteriophage CJ_CP_20-11-1 was observed to have a morphologically icosahedral head and a contractile tail approximately 100 nm long, and was found to belong to the Caudovirales order and Myoviridae family.

[0078] Example 4. Evaluation of pH stability of bacteriophage CJ_CP_20-11-1

[0079] To confirm whether bacteriophage CJ_CP_20-11-1 is stable over a wide pH range, solutions of pH 4, 7, 7.5, and 10 (pH 4: 0.2 M sodium acetate solution; pH 7, 7.5: 0.2 M sodium phosphate solution; and pH 10: 0.2 M Tris-HCl solution) were prepared. 450 μL of each pH solution and 2 × 10 1050 μL of PFU / mL bacteriophage solution was mixed and allowed to stand at 4° C. for 2 hours, after which a double-layer agar plaque assay was performed to evaluate the increase or decrease in titer.

[0080] As a result, as shown in Figure 2, bacteriophage CJ_CP_20-11-1 was stable at pH 7 to 10 without losing activity, and even at pH 4, its activity decreased by about 1.7 logs compared to the group at pH 7.5, indicating that it is a bacteriophage with excellent acid resistance.

[0081] Example 5. Evaluation of the thermal stability of bacteriophage CJ_CP_20-11-1

[0082] To determine whether bacteriophage CJ_CP_20-11-1 is stable at high temperatures, 2 × 10 8 500 μL of the PFU / mL bacteriophage solution was left to stand at 60° C. for 0, 3, 6 or 24 hours, and then a double-layer agar plaque assay was performed to evaluate the increase or decrease in titer.

[0083] As a result, as shown in Figure 3, when exposed to 60°C for 3 hours, bacteriophage CJ_CP_20-11-1 showed an activity decrease of about 1.0 log compared to the control group exposed for 0 hours, when exposed for 6 hours, it showed an activity decrease of about 1.9 log compared to the control group, and even when exposed for 24 hours, it showed an activity decrease of about 5.5 log compared to the control group, but still showed activity. Therefore, it was found that bacteriophage CJ_CP_20-11-1 is a bacteriophage with excellent heat resistance.

[0084] Example 6. Evaluation of the lysis spectrum of bacteriophage CJ_CP_20-11-1

[0085] In order to evaluate the lytic spectrum of bacteriophage CJ_CP_20-11-1, CP strains isolated from fecal samples collected from livestock farmers in Seoul, Gyeonggi-do, Chungcheong-do, and Gyeongsang-do, Korea, and 45 CP strains provided by the National Veterinary Medical and Quarantine Service were cultured in BHI liquid medium, and then 50 μL of each of the cultured strains was inoculated into 5 mL of 0.7% soft agar, poured into a Petri dish, plated, and left to stand for 5 minutes. Then, 10 μL of the bacteriophage CJ_CP_20-11-1 concentrate obtained in Example 1-3 was spotted on the soft agar, and left to stand for 18 hours at 42° C. After the end of the culture, the lytic spectrum of bacteriophage CJ_CP_20-11-1 was evaluated based on the presence or absence of lytic plaques formed on the soft agar.

[0086] [Table 1]

[0087] As a result, as shown in Table 1, lytic plaques were formed in all 45 types of CP strains tested, confirming that bacteriophage CJ_CP_20-11-1 has the ability to kill a wide spectrum of CP strains.

[0088] From the above description, a person having ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical ideas or essential features. In this regard, it should be understood that the above-described embodiments are illustrative in all respects and are not limiting. The scope of the present invention should be interpreted as including all modifications or alterations derived from the meaning and scope of the claims set forth below in the detailed description of the invention, and their equivalent concepts. TIFF0007579986000002.tif249169

Claims

1. Bacteriophage CJ_CP_20-11-1 has a specific killing ability against Clostridium perfringens (CP) and has been deposited under the accession number KCCM12932P.

2. A composition for preventing or treating an infectious disease caused by Clostridium perfringens, comprising the bacteriophage CJ_CP_20-11-1 described in claim 1 as an active ingredient.

3. The composition according to claim 2, wherein the infectious disease caused by Clostridium perfringens is necrotizing enterocolitis.

4. An antibiotic comprising the bacteriophage CJ_CP_20-11-1 of claim 1 as an active ingredient.

5. A feed additive comprising the bacteriophage CJ_CP_20-11-1 according to claim 1 as an active ingredient.

6. A feed comprising the feed additive according to claim 5.

7. A drinking water additive comprising the bacteriophage CJ_CP_20-11-1 of claim 1 as an active ingredient.

8. 8. Drinking water comprising the drinking water additive of claim 7.

9. A disinfectant comprising the bacteriophage CJ_CP_20-11-1 of claim 1 as an active ingredient.

10. A cleaning agent comprising the bacteriophage CJ_CP_20-11-1 according to claim 1 as an active ingredient.

11. A method for preventing or treating an infectious disease caused by Clostridium perfringens, comprising administering the bacteriophage CJ_CP_20-11-1 described in claim 1 or the composition described in claim 2 to an animal other than a human.

12. The method of claim 11, wherein the infectious disease caused by Clostridium perfringens is necrotizing enterocolitis.

Citation Information

Patent Citations

  • Bacteriophage lysates as alternative antimicrobial agents

    JP2013539965A

  • Novel bacteriophage and antibacterial composition containing the same

    JP2016510979A

  • Novel bacteriophage and antibacterial composition containing the same

    JP2016518810A

  • Compositions containing bacteriophages and methods of using bacteriophages to treat infections

    US6942858B1